New hope for lung transplant patients: drug targets sudden lung failure
NCT ID NCT07538336
First seen Apr 22, 2026 · Last updated Apr 22, 2026
Summary
This study tests a drug called emapalumab in 40 adults who had a lung transplant and now have a sudden drop in lung function (acute lung allograft dysfunction). The goal is to see if the drug can help their lungs recover to near-normal levels within 90 days. Participants must be at least 10 months post-transplant and have high levels of certain immune markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.